Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of EGFR mutated NSCLC patients developing leptomeningeal metastases: ORA-LM study.
J W Tijmen van der WelMirjam C BoelensMerel JebbinkSietske A SmuldersKlaar W MaasMerel J A LuitseAnnette CompterRobin P B BoltjesNik SolKim MonkhorstDaan van den BroekEgbert F SmitAdrianus Johannes de LangenDieta BrandsmaPublished in: Neuro-oncology (2024)
In 27% of patients an RM was found in CSF ctDNA, none of which are targetable at time of writing, and clinical efficacy of osimertinib DE seems limited. There is much to gain in diagnostic as well as therapeutic strategies in EGFRm+ NSCLC LM.